BR9913201A - Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica - Google Patents
Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnicaInfo
- Publication number
- BR9913201A BR9913201A BR9913201-0A BR9913201A BR9913201A BR 9913201 A BR9913201 A BR 9913201A BR 9913201 A BR9913201 A BR 9913201A BR 9913201 A BR9913201 A BR 9913201A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- chronic fatigue
- fatigue syndrome
- substance
- fibromyalgia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: <B>"USO DE ANTAGONISTAS DA SUBSTâNCIA P PARA O TRATAMENTO DA SìNDROME DA FADIGA CRÈNICA E/OU FIBROMIALGIA E USO DE ANTAGONISTAS DO RECEPTOR DE NK-1 PARA TRATAMENTO DA SìNDROME DA FADIGA CRÈNICA"<D>. A invenção refere-se ao uso farmacêutico de antagonistas da substância P específicos, em particular antagonistas 1-acilpiperidina da substância P, especialmente, N-benzoil-2-benzil-4-(azanaftoil-amino)-piperidinas, por exemplo, de fórmula onde X e Y são cada qual, independentemente entre si N e/ou CH e o anel A é não-substituído ou mono- ou polissubstituído por substituintes selecionados do grupo que consiste em alquila inferior, alcóxi inferior, halogênio, nitro e trifluormetila; e sais farmaceuticamente aceitáveis dos mesmos no tratamento da síndrome da fadiga crónica (CFS) na ausência de terapia inibidora da reabsorção de serotonina seletiva/agonista de serotonina ou para o tratamento de fibromialgia ou de sintomas funcionais associados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9818467.4A GB9818467D0 (en) | 1998-08-25 | 1998-08-25 | Organic compounds |
GBGB9826692.7A GB9826692D0 (en) | 1998-12-04 | 1998-12-04 | Organic compounds |
PCT/EP1999/006215 WO2000010545A2 (en) | 1998-08-25 | 1999-08-24 | Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913201A true BR9913201A (pt) | 2001-05-08 |
Family
ID=26314255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913201-0A BR9913201A (pt) | 1998-08-25 | 1999-08-24 | Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica |
Country Status (14)
Country | Link |
---|---|
US (5) | US20030092735A1 (pt) |
EP (1) | EP1107744B1 (pt) |
JP (1) | JP4510290B2 (pt) |
CN (1) | CN1216598C (pt) |
AT (1) | ATE238044T1 (pt) |
AU (1) | AU5624599A (pt) |
BR (1) | BR9913201A (pt) |
CA (1) | CA2339628C (pt) |
DE (1) | DE69907220T2 (pt) |
DK (1) | DK1107744T3 (pt) |
ES (1) | ES2198948T3 (pt) |
PT (1) | PT1107744E (pt) |
TW (1) | TW200529847A (pt) |
WO (1) | WO2000010545A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002158A1 (en) | 1996-07-17 | 1998-01-22 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
DK1107744T3 (da) * | 1998-08-25 | 2003-07-28 | Wolfgang Mueller | Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi |
UA76810C2 (uk) † | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
GB0220953D0 (en) | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
EP1548711A4 (en) * | 2002-09-30 | 2009-01-21 | Nec Corp | RECORDING PARAMETER FIXING METHOD AND DATA RECORDER USING THE SAME |
GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
JP2010519312A (ja) * | 2007-02-23 | 2010-06-03 | アベラ ファーマシューティカルズ, インコーポレイテッド | 薬学的製剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
AU648317B2 (en) * | 1990-06-01 | 1994-04-21 | Pfizer Inc. | 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them |
MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
JPH05262654A (ja) * | 1992-03-18 | 1993-10-12 | Kaken Pharmaceut Co Ltd | 慢性疲労症候群治療剤 |
TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
ES2229259T3 (es) * | 1995-01-12 | 2005-04-16 | Glaxo Group Limited | Derivados de piperidina con actividad antagonista de taquiquinina. |
AU4918796A (en) | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
RU2156250C2 (ru) * | 1995-04-24 | 2000-09-20 | Новартис Аг | Производные хромона, способ их получения и фармацевтическая композиция |
TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
JPH11505547A (ja) | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | ナルトレキソン及び関連化合物を用いる禁煙処置 |
WO1997038692A1 (en) | 1996-04-12 | 1997-10-23 | Eli Lilly And Company | Bisindoles for treating pain or nociception |
US5891875A (en) * | 1996-05-20 | 1999-04-06 | Eli Lilly And Company | Morpholinyl tachykinin receptor antagonists |
US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
CA2273810A1 (en) | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating major depressive disorders |
WO1999017609A1 (en) * | 1997-10-07 | 1999-04-15 | Larreacorp, Ltd. | Nontoxic extract of larrea tridentata and method of making the same |
DK1107744T3 (da) * | 1998-08-25 | 2003-07-28 | Wolfgang Mueller | Anvendelse af substans P antagonister i behandlingen af kronisk træthedssyndrom og/eller fibromyalgi |
-
1999
- 1999-08-24 DK DK99942911T patent/DK1107744T3/da active
- 1999-08-24 WO PCT/EP1999/006215 patent/WO2000010545A2/en active IP Right Grant
- 1999-08-24 CA CA002339628A patent/CA2339628C/en not_active Expired - Fee Related
- 1999-08-24 AT AT99942911T patent/ATE238044T1/de active
- 1999-08-24 CN CN99810017XA patent/CN1216598C/zh not_active Expired - Fee Related
- 1999-08-24 ES ES99942911T patent/ES2198948T3/es not_active Expired - Lifetime
- 1999-08-24 JP JP2000565867A patent/JP4510290B2/ja not_active Expired - Fee Related
- 1999-08-24 PT PT99942911T patent/PT1107744E/pt unknown
- 1999-08-24 AU AU56245/99A patent/AU5624599A/en not_active Abandoned
- 1999-08-24 BR BR9913201-0A patent/BR9913201A/pt not_active Application Discontinuation
- 1999-08-24 EP EP99942911A patent/EP1107744B1/en not_active Expired - Lifetime
- 1999-08-24 DE DE69907220T patent/DE69907220T2/de not_active Expired - Lifetime
- 1999-08-31 TW TW094103860A patent/TW200529847A/zh unknown
-
2002
- 2002-08-16 US US10/222,060 patent/US20030092735A1/en not_active Abandoned
-
2004
- 2004-09-23 US US10/947,967 patent/US20050096334A1/en not_active Abandoned
-
2007
- 2007-03-08 US US11/715,805 patent/US20070155759A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/008,777 patent/US7713984B2/en not_active Expired - Fee Related
-
2009
- 2009-11-13 US US12/618,388 patent/US20100055176A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000010545A2 (en) | 2000-03-02 |
CA2339628A1 (en) | 2000-03-02 |
EP1107744A2 (en) | 2001-06-20 |
DE69907220D1 (de) | 2003-05-28 |
JP2002523363A (ja) | 2002-07-30 |
CN1348372A (zh) | 2002-05-08 |
DE69907220T2 (de) | 2004-02-05 |
DK1107744T3 (da) | 2003-07-28 |
US20050096334A1 (en) | 2005-05-05 |
EP1107744B1 (en) | 2003-04-23 |
US20070155759A1 (en) | 2007-07-05 |
CA2339628C (en) | 2008-06-03 |
US7713984B2 (en) | 2010-05-11 |
US20030092735A1 (en) | 2003-05-15 |
ES2198948T3 (es) | 2004-02-01 |
WO2000010545A3 (en) | 2000-08-10 |
JP4510290B2 (ja) | 2010-07-21 |
ATE238044T1 (de) | 2003-05-15 |
CN1216598C (zh) | 2005-08-31 |
US20100055176A1 (en) | 2010-03-04 |
US20080161329A1 (en) | 2008-07-03 |
AU5624599A (en) | 2000-03-14 |
PT1107744E (pt) | 2003-08-29 |
TW200529847A (en) | 2005-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schreiber et al. | Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’antipsychotics, clozapine and risperidone | |
DK1177187T3 (da) | Diarylsyrederivater som PPAR-receptorligander | |
BRPI0414450A (pt) | derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica | |
NO20032253L (no) | Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer | |
BRPI0410933A (pt) | novos antagonistas do receptor p2x7 e seu uso | |
DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
BR0016396A (pt) | Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares | |
BRPI0418102A (pt) | derivados de quinolina | |
DE602004021921D1 (de) | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten | |
BR0209580A (pt) | Derivados de ciclohexan-1, 4 diamina substituìdos | |
ITRM20010356A1 (it) | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. | |
EA200200649A1 (ru) | Комбинация ингибитора обратного захвата серотонина и антагониста, обратного агониста или неполного агониста 5-нт2с-рецептора | |
BR9913201A (pt) | Uso de antagonista da substância p para o tratamento da sìndrome da fadiga crÈnica e/ou fibromialgia e uso de antagonistas do recptor de nk-1 para tratamento da sìndrome da fadiga crÈnica | |
BR0311436A (pt) | Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6 | |
PT1254134E (pt) | Derivados de 1,3-di-hidro-2h-indol-2-ona e sua utilizacao como ligandos para os receptores v1b ou v1b e v1a da arginina-vasopressina | |
BR0007718A (pt) | Utilização de derivados depiridazino[4,5-b]indol-1-acetamida para preparaçãode medicamentos para doenças ligadas à disfunçãode receptores de benzodiazepina do tipoperiférico | |
BR0011329A (pt) | Antagonistas do recptor de bradicinina | |
BR0316895A (pt) | Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
BR9714215A (pt) | Derivados de benzoato de 1,4-diazabiciclo[2.2.2]oct-2-ilmetila, seu preparo e sua aplicação em terapêutica | |
HUP0303513A2 (hu) | Szubsztituált pirazinkinoxalin-származékok mint szerotonin receptor agonisták és antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
BR0014712A (pt) | Uso de derivados carbonilamino contra distúrbios do snc | |
FR2801585B1 (fr) | Nouveaux antagonistes des recepteurs de l'ii-8 | |
BR0215272A (pt) | Derivados imidazoquinolina | |
BR9812752A (pt) | Derivados de 8-azabiciclo [3.2.1] octano-3-metanamina enquanto ligandos dos receptores de dopamina d2 e d3 e de serotonina 5ht1a e 5ht2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL.8: A61K 31/4468, A61K 31/4709, A61K 31/4725, A61K 31/517, A61P 25/04, A61P 29/02, A61P 43/00 Ipc: A61K 31/4468 (2007.10), A61K 31/4709 (2007.10), A6 |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI. |
|
B09T | Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette] |
Free format text: REFERENTE A RPI 2043 DE 02/03/2010. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |